These findings suggest that in resistant BCC, AP-1 shapes the chromatin accessibility landscape to open alternative Smad3 binding sites, allowing AP-1 and Smad3 to cooperatively induce expression of Rho regulators including GEFs. The gene discussed is RHO; the disease is skin basal cell carcinoma.